A Multicenter, Randomized, Double-blind, Placebo- Controlled Phase III Study Evaluating the Efficacy and Safety of HRS-1780 in Adult Participants With Chronic Kidney Disease
Latest Information Update: 24 Feb 2026
At a glance
- Drugs HRS 1780 (Primary)
- Indications Renal failure
- Focus Registrational; Therapeutic Use
- Sponsors Shandong Suncadia Medicine
Most Recent Events
- 24 Feb 2026 New trial record